Bisphenol F diglycidyl ether (BFDE) is a synthetic epoxy resin monomer. It is produced by reacting bisphenol F with epichlorohydrin. BFDE is used in a wide range of applications, including adhesives, coatings, and composites. It is also used in the production of electronics and other industrial products. BFDE has been shown to have some potential health effects, including endocrine disruption. Studies on BFDE have been conducted to assess its potential impact on human health and the environment. Research focuses on its environmental fate, potential toxicity, and bioaccumulation.'
bisphenol F diglycidyl ether: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
bisphenol F diglycidyl ether : An aromatic ether that is bisphenol F where the hydrogens of both hydroxy groups have been replaced by a oxiran-2-ylmethyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 91511 |
| CHEMBL ID | 3182674 |
| CHEBI ID | 142451 |
| SCHEMBL ID | 194748 |
| MeSH ID | M0384214 |
| Synonym |
|---|
| oxirane, 2,2'-[methylenebis(4,1-phenyleneoxymethylene)]bis- |
| bis[4-[(oxiran-2-yl)methoxy]phenyl]methane |
| einecs 218-257-4 |
| 2,2'-(methylenebis(p-phenyleneoxymethylene))bisoxirane |
| bfdge |
| bis(4-(glycidyloxy)phenyl)methane |
| bisphenol f diglycidyl ether |
| FT-0663373 |
| p,p-bfdge |
| 2,2'-[methylenebis(4,1-phenyleneoxymethylene)]bis(oxirane) |
| CHEBI:142451 |
| para-para-bfdge |
| diphenylolmethane diglycidyl ether |
| 2,2'-[methylenebis(4,1-phenyleneoxymethylene)]bisoxirane |
| 2095-03-6 |
| bis(4-glycidyloxyphenyl)methane |
| 2-[[4-[[4-(oxiran-2-ylmethoxy)phenyl]methyl]phenoxy]methyl]oxirane |
| NCGC00249079-01 |
| dtxsid4044872 , |
| cas-2095-03-6 |
| bis[4-(glycidyloxy)phenyl]methane |
| tox21_303420 |
| dtxcid2024872 |
| NCGC00257258-01 |
| tox21_201598 |
| NCGC00259147-01 |
| unii-v3625oqu1k |
| oxirane, 2,2'-(methylenebis(4,1-phenyleneoxymethylene))bis- |
| ccris 9460 |
| v3625oqu1k , |
| methane, bis(p-(2,3-epoxypropoxy)phenyl)- |
| AKOS015912998 |
| bis[p-(2,3-epoxypropoxy)phenyl]methane |
| 4,4'-methylenebisphenol diglycidyl ether |
| bis(4-hydroxyphenyl)methane diglycidyl ether |
| SCHEMBL194748 |
| benzene, 1,1'-methylenebis[4-[(2-oxiranyl)methoxy]- |
| 2-((4-[4-(2-oxiranylmethoxy)benzyl]phenoxy)methyl)oxirane # |
| bisphenol f diglycidyl ether, para-para' |
| methane, bis[p-(2,3-epoxypropoxy)phenyl]- |
| bis(p-hydroxyphenyl)methane diglycidyl ether |
| 4,4'-methylenediphenol diglycidyl ether |
| CHEMBL3182674 |
| 2-{[4-({4-[(oxiran-2-yl)methoxy]phenyl}methyl)phenoxy]methyl}oxirane |
| bis(4-(oxiran-2-ylmethoxy)phenyl)methane |
| mfcd00799483 |
| CS-0204375 |
| Q27291479 |
| F83002 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Bisphenol A (BPA) is a widely studied typical endocrine-disrupting chemical, and one of the major new issues is the safe replacement of this commonly used compound." | ( A new chapter in the bisphenol A story: bisphenol S and bisphenol F are not safe alternatives to this compound. Benachi, A; Eladak, S; Grisin, T; Guerquin, MJ; Habert, R; Livera, G; Moison, D; N'Tumba-Byn, T; Pozzi-Gaudin, S; Rouiller-Fabre, V, 2015) | 0.42 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Then, using the FeTA system without LH (the experimental conditions in which mouse and human fetal testes are most sensitive to BPA), we found that, as for BPA, 10 nmol/L BPS or BPF is sufficient to decrease basal testosterone secretion by human fetal testes with often nonmonotonic dose-response curves." | ( A new chapter in the bisphenol A story: bisphenol S and bisphenol F are not safe alternatives to this compound. Benachi, A; Eladak, S; Grisin, T; Guerquin, MJ; Habert, R; Livera, G; Moison, D; N'Tumba-Byn, T; Pozzi-Gaudin, S; Rouiller-Fabre, V, 2015) | 0.42 |
| Class | Description |
|---|---|
| aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
| epoxide | Any cyclic ether in which the oxygen atom forms part of a 3-membered ring. |
| diarylmethane | Any compound containing two aryl groups connected by a single C atom. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 49.2818 | 3.1890 | 29.8841 | 59.4836 | AID1224846; AID1224894 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 48.0034 | 0.0060 | 38.0041 | 19,952.5996 | AID1159523 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 22.8778 | 0.0007 | 14.5928 | 83.7951 | AID1259368; AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 41.6635 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743063 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 55.8011 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259378 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 56.9313 | 0.0002 | 14.3764 | 60.0339 | AID720691; AID720692 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 68.5896 | 0.0030 | 41.6115 | 22,387.1992 | AID1159553 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 34.8387 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 40.9090 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 64.9996 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 53.9432 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075; AID743078 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 57.5766 | 0.0010 | 24.5048 | 61.6448 | AID743212; AID743215 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 41.2521 | 0.0010 | 19.4141 | 70.9645 | AID743094; AID743140; AID743191 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 44.3538 | 0.0237 | 23.2282 | 63.5986 | AID743222; AID743223; AID743241 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 68.8687 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 38.3953 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1224895 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 51.5414 | 0.1434 | 27.6121 | 59.8106 | AID1159516; AID1159519 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 61.9089 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 38.8952 | 0.0578 | 21.1097 | 61.2679 | AID1159526 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 113.0040 | 0.0391 | 47.5451 | 146.8240 | AID1224845 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 23.7622 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 58.4106 | 0.0420 | 27.3789 | 61.6448 | AID743210 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 62.1642 | 0.0006 | 27.2152 | 1,122.0200 | AID743202; AID743219 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 36.7459 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID720552 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 68.8687 | 0.0119 | 17.9420 | 71.5630 | AID651632; AID720516 |
| Ataxin-2 | Homo sapiens (human) | Potency | 68.8687 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (48.72) | 29.6817 |
| 2010's | 14 (35.90) | 24.3611 |
| 2020's | 6 (15.38) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.95) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (2.44%) | 5.53% |
| Reviews | 1 (2.44%) | 6.00% |
| Case Studies | 2 (4.88%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 37 (90.24%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||